AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read

Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO

TRex Bio, backed by Eli Lilly, aims to raise up to $133M in its U.S. IPO, selling 8.3M shares at $14-$16 each. The biotech focuses on anti-inflammatory drugs and has partnerships with Lilly, Johnson & Johnson, and others. Lilly plans to maintain its 19.9% stake.

Original reporting
tradingview.com
Published Oct 6, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 4:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The filing introduces a new micro‑cap biotech to the market, offering investors exposure to its pipeline targeting atopic dermatitis and alopecia areata.

02

Market read

Primary relevance is the new IPO offering; limited immediate market impact beyond biotech investors.

03

What to watch

Potential strategic value to Eli Lilly and J&J partners could drive post‑IPO demand.

Relevance 7/10Novelty 8/10Timing: today

Background

TRex Bio, a San Francisco‑based anti‑inflammatory biotech backed by Eli Lilly, filed an SEC prospectus to raise up to $133M in a Nasdaq IPO.

Market effects

Sector

Adds another biotech IPO candidate, modest impact on the broader biotech sector.

Regional

Limited to US Nasdaq listings; no broader regional effect.

Global

Low global relevance; primarily of interest to US biotech investors.

Counterpoint

What could challenge this read

The IPO size is modest and the company is still pre-revenue; investors may be wary of dilution.

Key entities

  • company
    TRex Bio

    Biotech seeking Nasdaq IPO, ticker not yet assigned.

  • company
    Eli Lilly

    Backer and 19.9% stakeholder in TRex Bio.

  • company
    Johnson & Johnson

    Strategic partner in TRex Bio collaborations.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 5
High

Immunology startup TRex Bio sets price range for $133 million public debut

TRex Bio Inc., a biotech firm developing autoimmune treatments, aims to raise $133.3M in an IPO, offering 8.33M shares at $14-$16 each. The company's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027. Backed by investors like Eli Lilly and Pfizer Ventures, TRex Bio plans to use proceeds for clinical development and operations. It will list on Nasdaq under 'TRXB'.

investing.com2 min
SEP 18
MedAI 8/10

Trex Bio files for Nasdaq IPO; Eli Lilly eyes 19.9% stake

Trex Bio filed for a Nasdaq IPO under the ticker TRXB, with Eli Lilly planning to acquire up to 19.9% stake. The company's pipeline includes TRB-071 and TRB-051, with Eli Lilly partnering on the latter. Underwriters include J.P. Morgan, Evercore ISI, and others. The IPO aims to raise capital and establish a strategic partnership with Eli Lilly.

scanx.trade3 min
SEP 14
$TREXMed

Trex at Goldman Sachs conference: demand, growth plan lift outlook

Trex Company (TREX) raised its full-year 2026 net sales guidance to mid single-digit growth from low single-digit, citing stronger demand and operational improvements. The company expects about $1.25 billion in revenue by year-end 2026 and reaffirmed its long-term goal of $2 billion in revenue by 2030. Management highlighted growth from lower-priced products, a faster ramp at its new Little Rock plant, and strategic distribution changes.

investing.com2 min
AUG 11
$TREXMedAI 8/10

Trex (TREX) Q2 2026 Earnings Call Transcript

Trex Company (TREX) reported Q2 2026 net sales of $418 million, up 8%, with gross margin at 37.9% (down from 40.8%). Adjusted diluted EPS was $0.62 and adjusted EBITDA $112 million. Full-year 2026 guidance: net sales $1.215B to $1.25B, adjusted EBITDA $335M to $350M. The company authorized $150M more buybacks and accelerated its Little Rock facility ramp-up.

fool.com6 min